Trial Profile
Efficacy and safety of rituximab in patients with severe, treatment-refractory interstitial lung disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2014
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Interstitial lung diseases
- Focus Adverse reactions; Therapeutic Use
- 18 Aug 2014 New trial record